Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

0.09USD
4:02pm EDT
Change (% chg)

$-0.00 (-3.33%)
Prev Close
$0.09
Open
$0.09
Day's High
$0.09
Day's Low
$0.09
Volume
143,900
Avg. Vol
319,678
52-wk High
$0.60
52-wk Low
$0.06

Latest Key Developments (Source: Significant Developments)

Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine
Monday, 6 Mar 2017 08:00am EST 

Cel-sci Corp : Cel-Sci gives update on partial clinical hold on phase 3 head and neck cancer study with multikine . Cel-Sci - pursuant to partial clinical hold, patients currently receiving study treatments can continue to receive treatment at discretion of physicians . Cel-Sci - patients already enrolled in multikine drug study will continue to be followed . Cel-Sci-To provide updated investigator's brochure, procedures for compliance with requirements under 21 cfr 312 subpart d to address partial clinical hold . Cel-Sci - to provide to FDA list of major protocol deviations, which cel-sci believes will "affect study results" .Cel-Sci - to provide FDA a plan to identify major protocol deviations across all patients enrolled in phase 3 protocol for multikine drug.  Full Article

Cel-Sci says FDA issued incomplete response to hold letter to co
Thursday, 22 Dec 2016 04:53pm EST 

Cel-sci Corp : On December 16, FDA issued incomplete response to hold letter to co . Cel-Sci Corp - FDA's incomplete response to hold letter indicates co's Nov 18 submission is not complete response to all issues listed in FDA's clinical hold letter . Cel-Sci Corp- plans to send FDA a request for an in person meeting with agency to discuss all matters relating to partial clinical hold . Cel-Sci Corp- should FDA lift partial clinical hold remaining cost of phase 3 clinical trial will be higher than currently estimated . Cel-Sci Corp- reviewing all options in response to FDA's incomplete response to hold letter - sec filing .Cel-Sci Corp- estimate total remaining cash cost of phase 3 clinical trial, excluding any costs to be paid by partners, would be about $12.1 million.  Full Article

CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial
Monday, 21 Nov 2016 08:30am EST 

Cel-sci Corp : CEL-SCI Corp - submitted response to FDA regarding partial clinical hold of CEL-SCI's phase 3 clinical trial of its investigational drug multikine .CEL-SCI submits response to fda in connection with partial clinical hold on phase 3 clinical trial.  Full Article

CEL-SCI reports clinical hold on head, neck cancer study
Monday, 26 Sep 2016 11:03pm EDT 

CEL-SCI Corp : Says CEL-SCI reports clinical hold on head and neck cancer study .CEL-SCI Corp says was also told to expect formal letter from FDA within 30 days and will work diligently with FDA to obtain release of clinical hold.  Full Article

CEL-SCI says arbitration hearing scheduled to begin on Sept 26 - sec filing
Friday, 2 Sep 2016 06:28am EDT 

CEL-SCI Corp : CEL-SCI arbitration hearing, brought by co against former CRO is scheduled to begin on Sept 26 - SEC filing Source: (http://bit.ly/2c9PUsU) Further company coverage: [CVM.A] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cel-Sci Q3 loss per share $0.03
Wednesday, 10 Aug 2016 08:00am EDT 

Cel-Sci Corp : Sci Corp reports third quarter fiscal year 2016 financial results .Q3 loss per share $0.03.  Full Article

Cel-Sci Corporation Q2 loss per share $0.07
Tuesday, 10 May 2016 04:40pm EDT 

Cel-Sci Corp : Cel-Sci corporation reports second quarter fiscal year 2016 financial results .Q2 loss per share $0.07.  Full Article

CEL-SCI Corp prices public offering for up to $12 mln
Friday, 23 Oct 2015 08:40am EDT 

CEL-SCI Corp:Prices public offering for up to $12 million.Says has priced a best efforts offering of common stock and warrants at a combined price of $0.67 per unit.  Full Article

CEL-SCI announces closing of public offering for gross proceeds of $16 mln
Friday, 29 May 2015 08:00am EDT 

CEL-SCI Corp:Has closed efforts offering of 20,253,164 shares of common stock and 20,253,164 warrants to purchase shares of common stock.The common stock and warrants were sold at a combined price of $0.79 per unit of securities and resulted in aggregate gross proceeds of $16 million, prior to deducting placement agent commissions and offering expenses, and excluding the exercise of any warrants.The common stock and warrants will separate immediately.The warrants are immediately exercisable, expire May 28, 2020 and have an exercise price of $0.79 per share.  Full Article

CEL-SCI prices up to $16 million public offering of common stock and warrants
Friday, 22 May 2015 09:04am EDT 

CEL-SCI:Prices common stock and warrants at a combined price of $0.79 per unit of securities for aggregate gross proceeds of up to $16 million, prior to deducting placement agent commissions and offering expenses.Says each unit consists of one share of common stock and one warrant to purchase one share of common stock.Says common stock and warrants will separate immediately.Warrants are immediately exercisable, expire in five-years and have an exercise price of $0.79 per share.Says this offering is expected to close on or about May 28, 2015.CEL-SCI intends to use the net proceeds of the offering for its Phase III clinical trial, an ongoing Phase I study in HIV/HPV co-infected patients other research and development.Also uses for repayment of a $1.1 million note, held in a trust of which the Company's chief executive officer is the trustee and a beneficiary, due in July 2015 and general and administrative expenses.Dawson James Securities, Inc. is acting as the sole placement agent for the proposed offering on a best efforts basis.  Full Article

More From Around the Web

BRIEF-Cel-Sci Corp scientist presents new findings for rheumatoid arthritis treatment vaccine

* Cel-Sci Corp - Cel-Sci scientist presents new findings for rheumatoid arthritis treatment vaccine